Literature DB >> 16239382

Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}.

K L Winthrop1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16239382      PMCID： PMC1766906          DOI： 10.1136/ard.2005.042390

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  11 in total

Review 1.  Infections and anti-tumor necrosis factor alpha therapy.

Authors:  Todd Ellerin; Robert H Rubin; Michael E Weinblatt
Journal:  Arthritis Rheum       Date:  2003-11

2.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

3.  Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.

Authors:  C M Nolan; S V Goldberg; S E Buskin
Journal:  JAMA       Date:  1999-03-17       Impact factor: 56.272

Review 4.  Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review.

Authors:  Madhukar Pai; Lee W Riley; John M Colford
Journal:  Lancet Infect Dis       Date:  2004-12       Impact factor: 25.071

Review 5.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

Authors:  Michael A Gardam; Edward C Keystone; Richard Menzies; Steven Manners; Emil Skamene; Richard Long; Donald C Vinh
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

6.  Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management.

Authors:  N Singh; D L Paterson
Journal:  Clin Infect Dis       Date:  1998-11       Impact factor: 9.079

Review 7.  TNF-alpha blockade and tuberculosis: better look before you leap.

Authors:  S M Arend; F C Breedveld; J T van Dissel
Journal:  Neth J Med       Date:  2003-04       Impact factor: 1.422

8.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Authors:  R S Wallis; M S Broder; J Y Wong; M E Hanson; D O Beenhouwer
Journal:  Clin Infect Dis       Date:  2004-04-15       Impact factor: 9.079

9.  Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.

Authors:  Aparna K Mohan; Timothy R Coté; Joel A Block; Augustine M Manadan; Jeffrey N Siegel; M Miles Braun
Journal:  Clin Infect Dis       Date:  2004-07-16       Impact factor: 9.079

Review 10.  Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection.

Authors:  JoAnn M Tufariello; John Chan; JoAnne L Flynn
Journal:  Lancet Infect Dis       Date:  2003-09       Impact factor: 25.071
View more
  6 in total

1.  [Centrofacial granulomatous inflammation].

Authors:  J Maetzke; R Hinrichs; A Sigge; K Scharffetter-Kochanek
Journal:  Hautarzt       Date:  2007-11       Impact factor: 0.751

2.  Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study.

Authors:  Hilary A Capell; Rajan Madhok; Duncan R Porter; Robin A L Munro; Iain B McInnes; John A Hunter; Malcolm Steven; Asad Zoma; Elaine Morrison; Martin Sambrook; Fat Wui Poon; Rosemary Hampson; Fiona McDonald; Ann Tierney; Neil Henderson; Ian Ford
Journal:  Ann Rheum Dis       Date:  2006-08-22       Impact factor: 19.103

3.  SLE and Tuberculosis: A Case Series and Review of Literature.

Authors:  Prasanta Kumar Bhattacharya; Md Jamil; Aakash Roy; Kishore Kumar Talukdar
Journal:  J Clin Diagn Res       Date:  2017-02-01

4.  IFNG +874T/A, IL10 -1082G/A and TNF -308G/A polymorphisms in association with tuberculosis susceptibility: a meta-analysis study.

Authors:  Antonio Guilherme Pacheco; Cynthia Chester Cardoso; Milton Ozório Moraes
Journal:  Hum Genet       Date:  2008-04-15       Impact factor: 4.132

5.  Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities.

Authors:  Tore K Kvien; Alejandro Balsa; Neil Betteridge; Maya H Buch; Patrick Durez; Ennio Giulio Favalli; Guillaume Favier; Cem Gabay; Rinie Geenen; Ioanna Gouni-Berthold; Frank van den Hoogen; Alison Kent; Lars Klareskog; Mikkel Ostergaard; Karel Pavelka; Joaquim Polido Pereira; Anne Grete Semb; Magnus Sköld; Maxime Dougados
Journal:  RMD Open       Date:  2020-07

Review 6.  Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease.

Authors:  Alfonso Motolese; Manuela Ceccarelli; Laura Macca; Federica Li Pomi; Ylenia Ingrasciotta; Giuseppe Nunnari; Claudio Guarneri
Journal:  Biomedicines       Date:  2022-01-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.